Polyclonal rabbit antithymocyte globulin (thymoglobulin): immunomodulatory effects and new aspects of its clinical application


Cite item

Full Text

Abstract

Antithymocyte immunoglobulins remain to be one of the most effective immunosuppressants used in transplantology and in the treatment of autoimmune diseases. The unique features of the mechanisms of individual antithymocyte globulin preparations should be borne in mind. Due to its polyclonal nature, thymoglobulin provides a wide spectrum of diverse immunomodulatory effects, which is the basis for its wide use in order to reduce the risk for graft rejection and a graft-versus-host reaction and to treat aplastic anemia.

About the authors

A D Kulagin

Novosibirsk State Medical University, Russian Agency for Health Care

Email: kulagingem@rambler.ru
кафедра клинической иммунологииканд. мед. наук., доц; ГОУ ВПО "Новосибирский государственный медицинский университет Росздрава"; Novosibirsk State Medical University, Russian Agency for Health Care

I A Lisukov

Novosibirsk State Medical University, Russian Agency for Health Care

Email: igor_lisukov@mail.ru
кафедра клинической иммунологиид-р мед. наук, проф; ГОУ ВПО "Новосибирский государственный медицинский университет Росздрава"; Novosibirsk State Medical University, Russian Agency for Health Care

I A Miloserdov

Acad. V. I. Shumakov Research Center of Transplantology and Artificial Organs, Ministry of Health and Social Development

Email: kidneytrans@mail.ru
Acad. V. I. Shumakov Research Center of Transplantology and Artificial Organs, Ministry of Health and Social Development

B V Afanasyev

Acad. I. P. Pavlov Saint Petersburg State Medical University

Email: bmt-director@spmu.rssi.ru
Acad. I. P. Pavlov Saint Petersburg State Medical University

References

  1. Metchnikoff E. Etudes sur la resorption des cellules. Ann. Inst. Pasteur. 1899; 17: 737.
  2. Woodruff M. F. A., Forman B. Effects of antilymphocyte serum on suspension of lymphocytes in vitro. Nature 1951; 168 (4262): 36-36.
  3. Starzl T. E. Heterologous antilymphocyte globulin. N. Engl. J. Med. 1968; 279 (13): 700-703.
  4. Mohty M., Gaugler B. Mechanisms of action of antithymocyte globulin: old dogs with new tricks! Leukemia and Lymphoma 2008; 49 (9): 1664-1667.
  5. Lebranchu Y. Polyclonal antilymphocyte antibodies. In: Grinyo J., Lebranchu Y., eds. New uses of biological agents in organ transplantation. Barcelona, Permanyer; 2008. 1-13.
  6. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21 (7): 1387- 1394.
  7. Bagicalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant. 2005; 35 (3): 225-231.
  8. Pre'ville X., Flacher M., LeMauff B. et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71 (3): 460-468.
  9. Raefsky E. L., Gascon P., Gratwohl A. et al. Biological and immunological characterization of ATG and ALG. Blood 1996; 68 (3): 712-719.
  10. Genestier L., Fournel S., Flacher M. et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998; 91 (7): 2360-2368.
  11. Michallet M.-C., Saltel F., Preville X. et al. Cathepsin-B-dependent apoptosis triggered by antithymocyte globulins: a novel mechanism of T-cell depletion. Blood 2003; 102 (10): 3719-3726.
  12. Zand M. S., Vo T., Huggins J. et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79 (11): 1507-1515.
  13. Minamimura K., Gao W., Maki T. CD4+ regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody. J. Immunol. 2006; 176 (7): 4125-4132.
  14. Lopez M., Clarkson M. R., Albin M. et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J. Am. Soc. Nephrol. 2006; 17 (10): 2844-2853.
  15. FengX., Kajigaya S., Solomon E. E. et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 2008; 111 (7): 3675-3683.
  16. LaCorcia G., Swistak M, Lawendowski C. et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 2009; 87 (7): 966-974.
  17. Zeng D., Lewis D., Dejbakhsh-Jones S. et al. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J. Exp. Med. 1999; 189 (7): 1073- 1081.
  18. Lan F., Zeng D., Higuchi M. et al. Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells. J. Immunol. 2001; 167 (4): 2087-2096.
  19. Lan F., Zeng D., Higuchi M. et al. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD 1-reactive natural killer T cells. Biol. Blood Marrow Transplant. 2003; 9 (6): 355-363.
  20. Monti P., Allavena P., Di Carlo V., Piemonti L. Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int. Immunopharmacol. 2003; 3 (2): 189-196.
  21. Fang L., Fehse B., Engel M. et al. Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation 2005; 79 (3): 369-371.
  22. Gillet-Hladky S., de Carvalho C. M., Bernaud J. et al. Rabbit antithymocyte globulin inhibits monocyte-derived dendritic cells maturation in vitro and polarizes monocyte-derived dendritic cells towards tolerogenic dendritic cells expressing indoleamine 2,3-dioxygenase. Transplantation 2006; 82 (7): 965-974.
  23. Naujokat C., Berges C., Fuchs D. et al. Antithymocyte globulins suppress dendritic cell function by multiple mechanisms. Transplantation 2007; 83 (4): 485-497.
  24. Michallet M. C., Preville X., Flacher M. et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003; 75 (5): 657-662.
  25. Chappell D., Beiras-Fernandez A., Hammer C., Thein E. In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia/reperfusion in a primate model. Transplantation 2006; 81 (4): 552-558.
  26. Hunter R. F., Mold N. G., Mitchell R. B., Huang A. T. Differentiation of normal marrow and HL60 cells induced by antithymocyte globulin. Proc. Natl. Acad. Sci. USA 1985; 82 (14): 4823-4827.
  27. Huang A. T., Mold N. G., Zhang S.-F. Antithymocyte globulin stimulates human hematopoietic progenitor cells. Proc. Natl. Acad. Sci. USA 1987; 84 (16): 5942-5946.
  28. Huang A. T., Mold N. G. The role of CD45RO in antithymocyte globulin's stimulation of primitive haemopoietic cells. Br. J. Haematol. 1994; 88 (3): 643-646.
  29. Killick S. B., Marsh J. C., Gordon-Smith E. G. et al. Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia. Br. J. Haematol. 2000; 108 (3): 582-591.
  30. Flynn J., Cox C. V., Rizzo S. et al. Direct binding of antithymocyte globulin to haemopoietic progenitor cells in aplastic anaemia. Br. J. Haematol. 2003; 122 (2): 289-297.
  31. Chen G., Kook H., Zeng W. et al. Is there a direct effect of antithymocyte globulin on hematopoiesis? Hematol. J. 2004; 5 (3): 255-261.
  32. Ayuk F., Zander A., Kroger N. Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma. Ann. Hematol. 2009; 88 (5): 401-404.
  33. Zand M. S., Vo T., Huggins J. et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79 (11): 1507-1515.
  34. Timm M. M., Kimlinger T. K., Haug J. L. et al. Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma. Leukemia 2006; 20 (10): 1863-1869.
  35. Ayuk F., Perez-Simon A., Shimoni A. et al. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica 2008; 93 (9): 1343-1350.
  36. Lin S., Cosgrove C. J. Perioperative management of immunosuppression. Surg. Clin. N. Am. 2006; 86 (5): 1167-1183.
  37. Shapiro R., Young J. B., Milford E. L. et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am. J. Transplant. 2005; 5 (4, pt 2): 874-886.
  38. Charpentier B., Rostaing L., Berthoux F. et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003; 75 (6): 844-851.
  39. Mourad G., Garrigue V., Squifflet J. P. et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001; 72 (6): 1050-1055.
  40. Hardinger K. L., Schnitzler M. A., Koch M. J. et al. Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience. Transplantation 2006; 81 (9): 1285-1289.
  41. Hardinger K., Rhee S., Buchanan P. et al A prospective, randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 2008; 86 (7): 947-952.
  42. Hamawi K., Hakeam H., Raza S. et al. Тимоглобулин® versus ATF-Fresenius® for induction in renal transplant recipients: a prospective study. Transplantation 2006; 82 (suppl. 1): 475.
  43. Ducloux D., Kazory A., Challier B. et al. Long-term toxicity of ATF induction may vary with choice of agent: a single - center retrospective study. Transplantation 2004; 77 (7): 1029- 1033.
  44. Zuckermann A. O., Grimm M., Scerny M. et al. Improved long - term results with Thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit antithymocyte globulines. Transplantation 2000; 69 (9): 1890- 1898.
  45. Brennan D. C., Daller J. A., Lake K. D. et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N. Engl. J. Med. 2006; 355 (19): 1967-1977.
  46. Brennan D. C., Schnitzler M. A. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N. Engl. Med. 2008; 359 (16): 1736-1738.
  47. Schnitzler M. A., Buchanan P. M., Willoughby L. M. et al. Cost effectiveness of thymoglobulin compared to basiliximab in kidney transplant using multicenter randomized trial data. Am. J. Transplant. 2007; 7 (suppl. 2): 232.
  48. Noel C., Abramowicz D., Durand D. et al Daclizumab versus thymoglobulin in renal transplant recipients with a high immunological risk: Am. J. Transplant. 2007; 7 (suppl. 2): 233.
  49. Brennan D. C. Long-term trends in allograft survival. Adv. Chron. Kidney Dis. 2006; 13 (1): 11-17.
  50. Bückler M., Caillard S., Barbier S. et al. Sirolimus versus cyclosporine in kidney recipients receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-month course of steroids. Am. J. Transplant. 2007; 7 (11): 2522-2531.
  51. Knight R. J., Kerman R. H., Schoenberg L. et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 2004; 78 (6): 904-910.
  52. Matas A. J., Kandaswamy R., Gillingham K. J. et al Prednisone-free maintenance immunosuppression - a 5-year experience. Am. J. Transplant. 2005; 5 (10): 2473-2478.
  53. Callaghan C. J., Bradley J. A. Current status of renal transplantation. Methods Mol. Bud 2006; 333: 1-27.
  54. Gaber O., First M. R., Test R. J. et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66 (1): 29-37.
  55. Schnitzler M. A., Woodward R. S., Lowell J. A. et al Economics of the antithymocyte globulins Thymoglobulin and Atgam in the treatment of acute renal transplant rejection. Pharmacoeconomics 2000; 17 (3): 287-293.
  56. Mariat M., Alamartine E., Diab N. et al. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid - resistant rejection episodes in kidney transplant recipients. Transplant. 1998; 11 (3): 231- 236.
  57. Webster A. C., Pankhurst T., Rinaldi F. et al. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data. Transplantation 2006; 81 (7): 953-965.
  58. Young N. S., Calada R. T., Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108 (8): 2509-2519.
  59. Locasciulli A., Oneto R., Bacigalupo A. et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation. Haematologica 2007; 92 (1): 11-18.
  60. Maschan M. A., Novichkova G., Baidildina D. D. et al Horse ATG (ATGAM) versus rabbit ATG (Fresenius) for treatment of aplastic anaemia in children: results of prospective double-blind randomised single-centre trial. Bone Marrow Transplant 2004; 33 (suppl. 1): S27.
  61. Zheng Y., Liu Y., Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp. Hematol. 2006; 34 (7): 826-831.
  62. Bojtarova E., Mistrik M. Outcome of adult patients with severe aplastic anaemia treated with immunosuppressive treatment: a single-centre experience. Bone Marrow Transplant 2008; 41 (suppl. 1): S143.
  63. Stadler M., Germing U., Kliche K. O. et al. A prospective, randomised, phase II study of horse antithymocyte globulin and rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004; 18 (3): 460-465.
  64. Fang J. P., Xu H. G., Huang S. L. et al. Immunosuppressive treatment of aplastic anemia in Chinese children with antithymocyte globulin and cyclosporin. Pediatr. Hematol. Oncol. 2006; 23 (1): 45-50.
  65. Garg R., Faded S., Garcia-Manero G. et al. Phase II study of rabbit antithymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia advance online publication, 26 February 2009.
  66. Di Bona E., Rodeghiero F., Bruno B. et al. Rabbit antithymocyte globulin (r-ATT) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Br. J. Haematol. 1999; 107 (2): 330- 334.
  67. Scheinberg P., Nunez O., Young N. S. Retreatment with rabbit antithymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br. J. Haematol. 2006; 133 (6): 622-627.
  68. Marsh J. C. W., Ball S. E., Cavenagh J. et al. Guidelines for the diagnosis and management of aplastic anaemia. (доступен на сайте http://www.bcshguidelines.com/pdf/ aplastic_anaemia_261108.pdf)
  69. Remberger M., Storer B., Ringden O. et al. Association between pretransplant Thymoglobulin and reduced nonrelapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant. 2002; 29 (5): 391-397.
  70. Bacigalupo A., Lamparelli T., Barisione G. et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant- S) related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol. Blood Marrow Transplant. 2006; 12 (5): 560-565.
  71. Basara N., Baurmann H., Kolbe K. et al Antithymocyte globulin fof the prevention of graft- versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant. 2005; 35 (10): 1011- 1018.
  72. Zalyalov Y., Ganapiev B., Zinchenko A. et al. Thymoglobulin prophylaxis of chronic GvHD after full matched peripheral blood SCT. Bone Marrow Transplant. 2009; 43 (suppl. 1): S140.
  73. Remberger M., Mattsson J., Hausenberger D. et al. Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia. Eur. J. Haematol. 2008; 80 (5): 419- 428.
  74. Russell J. A., Turner A. R., Larratt L. et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol. Blood Marrow Transplant. 2007; 13 (2): 299-306.
  75. Lowsky R., Takahashi I., Liu Y. P. et al. Protective conditioning for acute graft-versus-host disease. N. Engl. J. Med. 2005; 353 (13): 1321-1331.
  76. Michallet M., Le Q. H., Mohty M. et al. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: A 10-year retrospective analysis from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Exp. Hematol. 2008; 36 (5): 535-544.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies